INFU Quote, Financials, Valuation and Earnings

Retractable Technologies has a net margin of 2.76% compared to InfuSystems Holdings's net margin of -18.58%. InfuSystems Holdings's return on equity of 4.33% beat Retractable Technologies's return on equity of -16.83%.

InfuSystems Holdings has a consensus price target of $14.13, signalling upside risk potential of 154.51%. On the other hand Retractable Technologies has an analysts' consensus of -- which suggests that it could fall by --. Given that InfuSystems Holdings has higher upside potential than Retractable Technologies, analysts believe InfuSystems Holdings is more attractive than Retractable Technologies.

InfuSystems Holdings has a beta of 1.755, which suggesting that the stock is 75.5% more volatile than S&P 500. In comparison Retractable Technologies has a beta of 2.083, suggesting its more volatile than the S&P 500 by 108.265%.

InfuSystems Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Retractable Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. InfuSystems Holdings pays -- of its earnings as a dividend. Retractable Technologies pays out -3.32% of its earnings as a dividend.

InfuSystems Holdings quarterly revenues are $33.8M, which are larger than Retractable Technologies quarterly revenues of $10.3M. InfuSystems Holdings's net income of $933K is higher than Retractable Technologies's net income of -$1.9M. Notably, InfuSystems Holdings's price-to-earnings ratio is 55.50x while Retractable Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for InfuSystems Holdings is 0.89x versus 0.59x for Retractable Technologies. Usually stocks with elevated PS ratios are considered overvalued.

VolitionRX has a net margin of 2.76% compared to InfuSystems Holdings's net margin of -1226.82%. InfuSystems Holdings's return on equity of 4.33% beat VolitionRX's return on equity of --.

InfuSystems Holdings has a consensus price target of $14.13, signalling upside risk potential of 154.51%. On the other hand VolitionRX has an analysts' consensus of $3.37 which suggests that it could grow by 501.2%. Given that VolitionRX has higher upside potential than InfuSystems Holdings, analysts believe VolitionRX is more attractive than InfuSystems Holdings.

InfuSystems Holdings has a beta of 1.755, which suggesting that the stock is 75.5% more volatile than S&P 500. In comparison VolitionRX has a beta of 1.092, suggesting its more volatile than the S&P 500 by 9.182%.

InfuSystems Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. VolitionRX offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. InfuSystems Holdings pays -- of its earnings as a dividend. VolitionRX pays out -- of its earnings as a dividend.

InfuSystems Holdings quarterly revenues are $33.8M, which are larger than VolitionRX quarterly revenues of $474.5K. InfuSystems Holdings's net income of $933K is higher than VolitionRX's net income of -$5.8M. Notably, InfuSystems Holdings's price-to-earnings ratio is 55.50x while VolitionRX's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for InfuSystems Holdings is 0.89x versus 36.22x for VolitionRX. Usually stocks with elevated PS ratios are considered overvalued.

Catheter Precision has a net margin of 2.76% compared to InfuSystems Holdings's net margin of -4291.67%. InfuSystems Holdings's return on equity of 4.33% beat Catheter Precision's return on equity of -65.84%.

InfuSystems Holdings has a consensus price target of $14.13, signalling upside risk potential of 154.51%. On the other hand Catheter Precision has an analysts' consensus of -- which suggests that it could grow by 419.62%. Given that Catheter Precision has higher upside potential than InfuSystems Holdings, analysts believe Catheter Precision is more attractive than InfuSystems Holdings.

InfuSystems Holdings has a beta of 1.755, which suggesting that the stock is 75.5% more volatile than S&P 500. In comparison Catheter Precision has a beta of -0.541, suggesting its less volatile than the S&P 500 by 154.132%.

InfuSystems Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Catheter Precision offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. InfuSystems Holdings pays -- of its earnings as a dividend. Catheter Precision pays out -- of its earnings as a dividend.

InfuSystems Holdings quarterly revenues are $33.8M, which are larger than Catheter Precision quarterly revenues of $96K. InfuSystems Holdings's net income of $933K is higher than Catheter Precision's net income of -$4.1M. Notably, InfuSystems Holdings's price-to-earnings ratio is 55.50x while Catheter Precision's PE ratio is 0.44x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for InfuSystems Holdings is 0.89x versus 1.03x for Catheter Precision. Usually stocks with elevated PS ratios are considered overvalued.

Xtant Medical Holdings has a net margin of 2.76% compared to InfuSystems Holdings's net margin of -10.04%. InfuSystems Holdings's return on equity of 4.33% beat Xtant Medical Holdings's return on equity of -35.34%.

InfuSystems Holdings has a consensus price target of $14.13, signalling upside risk potential of 154.51%. On the other hand Xtant Medical Holdings has an analysts' consensus of $1.75 which suggests that it could grow by 264.58%. Given that Xtant Medical Holdings has higher upside potential than InfuSystems Holdings, analysts believe Xtant Medical Holdings is more attractive than InfuSystems Holdings.

InfuSystems Holdings has a beta of 1.755, which suggesting that the stock is 75.5% more volatile than S&P 500. In comparison Xtant Medical Holdings has a beta of 0.413, suggesting its less volatile than the S&P 500 by 58.747%.

InfuSystems Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xtant Medical Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. InfuSystems Holdings pays -- of its earnings as a dividend. Xtant Medical Holdings pays out -- of its earnings as a dividend.

InfuSystems Holdings quarterly revenues are $33.8M, which are larger than Xtant Medical Holdings quarterly revenues of $31.5M. InfuSystems Holdings's net income of $933K is higher than Xtant Medical Holdings's net income of -$3.2M. Notably, InfuSystems Holdings's price-to-earnings ratio is 55.50x while Xtant Medical Holdings's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for InfuSystems Holdings is 0.89x versus 0.55x for Xtant Medical Holdings. Usually stocks with elevated PS ratios are considered overvalued.